Summary of published case series and clinical trials of rituximab treatment for chronic GVHD
| Reference(s) . | ORR, no./total no. (%) . | Response site . |
|---|---|---|
| Ratanatharathorn et al95 | 4/8 (50) | Cut, Lu, Ms, O |
| Canninga-van Dijk et al98 | 5/6 (83) | Cut, Li |
| Okamoto et al100 | NA | Cut |
| Zaja et al97 | (65) | Cut, Li, Ms, Lu, Gi, O |
| Cutler et al101 | 14/20 (70) | Cut, Ms, Li |
| Mohty et al99 | 10/15 (66) | Cut, Gi, Li, O |
| von Bonin et al103 | 9/13 (69) | Cut, Ms, O |
| Teshima et al102 | 3/7 (43) | Cut, Ms, O |
| Reference(s) . | ORR, no./total no. (%) . | Response site . |
|---|---|---|
| Ratanatharathorn et al95 | 4/8 (50) | Cut, Lu, Ms, O |
| Canninga-van Dijk et al98 | 5/6 (83) | Cut, Li |
| Okamoto et al100 | NA | Cut |
| Zaja et al97 | (65) | Cut, Li, Ms, Lu, Gi, O |
| Cutler et al101 | 14/20 (70) | Cut, Ms, Li |
| Mohty et al99 | 10/15 (66) | Cut, Gi, Li, O |
| von Bonin et al103 | 9/13 (69) | Cut, Ms, O |
| Teshima et al102 | 3/7 (43) | Cut, Ms, O |
GVHD indicates graft-versus-host disease; ORR, overall response rate; Cut, skin and mucous membranes; Lu, lung; Ms, musculoskeletal; O, other; Li, liver; NA, not available; and Gi, gastrointestinal.